Published in Ophthalmology on April 01, 1987
Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol (1995) 1.43
Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem (2009) 1.31
N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol (2010) 1.11
Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid. Mediators Inflamm (2013) 1.11
Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (2008) 1.10
PDGF receptors are activated in human epiretinal membranes. Exp Eye Res (2008) 1.06
Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol (2001) 1.00
A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am J Pathol (2011) 0.99
Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci (2009) 0.99
Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol (2013) 0.98
The pars plana incision: experimental studies, pathologic observations, and clinical experience. Trans Am Ophthalmol Soc (1991) 0.97
Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol Cell Biol (2012) 0.95
The complex interplay between ERK1/2, TGFβ/Smad, and Jagged/Notch signaling pathways in the regulation of epithelial-mesenchymal transition in retinal pigment epithelium cells. PLoS One (2014) 0.94
Upregulation of TGF-ß1 in experimental proliferative vitreoretinopathy is accompanied by epithelial to mesenchymal transition. Graefes Arch Clin Exp Ophthalmol (2013) 0.89
Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction. Br J Ophthalmol (1992) 0.88
Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy. Am J Pathol (2014) 0.80
Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells. Exp Eye Res (2012) 0.80
Inhibition of DNA Methylation and Methyl-CpG-Binding Protein 2 Suppresses RPE Transdifferentiation: Relevance to Proliferative Vitreoretinopathy. Invest Ophthalmol Vis Sci (2015) 0.78
Temporal regulation of CD81 following retinal injury in the rat. Neurosci Lett (2003) 0.78
Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro. Int Ophthalmol (2001) 0.77
Retinal pigment epithelial cells: autocrine and paracrine stimulation of extracellular matrix contraction. Graefes Arch Clin Exp Ophthalmol (1997) 0.76
The different roles of myosin IIA and myosin IIB in contraction of 3D collagen matrices by human fibroblasts. Exp Cell Res (2014) 0.76
Perfluoro-n-octane as a temporary intraocular tamponade in a staged approach to manage complex retinal detachments. Clin Ophthalmol (2015) 0.75
Ocular tolerance and efficacy of short-term tamponade with double filling of polydimethyloxane and perfluoro-n-octane. Clin Ophthalmol (2011) 0.75
Cell-mediated contraction of vitreous explants from chicken embryo: possibility of screening for therapeutic agents against proliferative vitreoretinal diseases. Mol Vis (2013) 0.75
[Vitreal-induced RPE cell traction. Investigation of pathological vitreous samples in an in vitro contraction model]. Ophthalmologe (2009) 0.75
The influence of systemic renin-angiotensin-inhibition on ocular cytokines related to proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol (2017) 0.75
Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol (1995) 2.03
Angiogenic activity from bovine retina: partial purification and characterization. Proc Natl Acad Sci U S A (1981) 1.94
Intraocular tamponade duration and success of macular hole surgery. Retina (1996) 1.91
Demonstration of vasoproliferative activity from mammalian retina. J Cell Biol (1980) 1.87
Endothelin: visualization of mRNAs by in situ hybridization provides evidence for local action. Proc Natl Acad Sci U S A (1989) 1.87
The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology (1993) 1.82
Refractive changes after scleral buckling surgery. Arch Ophthalmol (1989) 1.81
Transforming growth factor beta. A biologic chorioretinal glue. Arch Ophthalmol (1989) 1.71
Full-thickness macular hole formation in eyes with a pre-existing complete posterior vitreous detachment. Ophthalmology (1995) 1.60
Vitrectomy for idiopathic epiretinal membranes causing macular pucker. Br J Ophthalmol (1988) 1.47
Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology (1989) 1.45
Assessment of vision in idiopathic macular holes with macular microperimetry using the scanning laser ophthalmoscope. Ophthalmology (1993) 1.44
Distribution of iatrogenic retinal breaks in macular hole surgery. Ophthalmology (1995) 1.42
Nuclear sclerotic cataract after vitrectomy for idiopathic epiretinal membranes causing macular pucker. Am J Ophthalmol (1991) 1.42
Nuclear sclerosis after vitrectomy for idiopathic epiretinal membranes. Am J Ophthalmol (1988) 1.41
Silicone oil in the treatment of complicated retinal detachments. Ophthalmology (1987) 1.30
Adult tissues contain chemoattractants for vascular endothelial cells. Nature (1980) 1.30
Retinal pigment epithelial cells release an inhibitor of neovascularization. Arch Ophthalmol (1985) 1.30
The extracellular matrix of human retinal pigment epithelial cells in vivo and its synthesis in vitro. Invest Ophthalmol Vis Sci (1986) 1.28
Iatrogenic retinal breaks complicating pars plana vitrectomy. Ophthalmology (1990) 1.23
Retinal detachment after extracapsular cataract extraction with posterior chamber intraocular lens. Ophthalmology (1987) 1.23
Vitrectomy for macular traction caused by incomplete vitreous separation. Arch Ophthalmol (1988) 1.22
Prognostic indicators of success and failure in vitrectomy for diabetic retinopathy. Ophthalmology (1986) 1.14
Vitrectomy for impending idiopathic macular holes. Am J Ophthalmol (1988) 1.14
Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol (1985) 1.13
Hospitalization requirements after vitreoretinal surgery. Arch Ophthalmol (1988) 1.12
Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol (1984) 1.10
Indocyanine green angiography in multiple evanescent white-dot syndrome. Am J Ophthalmol (1994) 1.08
Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol (1985) 1.06
Resolution of an absolute scotoma and improvement of relative scotomata after successful macular hole surgery. Am J Ophthalmol (1993) 1.05
Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-beta 2, and gas tamponade. Am J Ophthalmol (1996) 1.01
In vitro inhibition of lens epithelial cell proliferation and migration. Ophthalmic Surg (1988) 1.00
Reoperation after failed macular hole surgery. Retina (1996) 0.98
Effects of TGF-beta and TGF-beta neutralizing antibodies on fibroblast-induced collagen gel contraction: implications for proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (1994) 0.96
Response of pig retinal pigment epithelium to laser photocoagulation in organ culture. Arch Ophthalmol (1989) 0.96
Gravity-dependent distribution of retinal pigment epithelial cells dispersed into the vitreous cavity. Retina (1986) 0.96
Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. Arch Ophthalmol (1985) 0.94
Posterior capsule opacification. An in vitro model. Arch Ophthalmol (1985) 0.93
Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study. Ophthalmology (1993) 0.93
Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2. Ophthalmology (1994) 0.93
Extension of retinal detachments as a complication of pneumatic retinopexy. Arch Ophthalmol (1986) 0.92
Cryotherapy enhances intravitreal dispersion of viable retinal pigment epithelial cells. Arch Ophthalmol (1985) 0.92
The demonstration of angiogenic activity from ocular tissues. Preliminary report. Ophthalmology (1980) 0.91
Thrombin infusion for the control of intraocular bleeding during vitreous surgery. Arch Ophthalmol (1985) 0.91
Vitrectomy for macular pucker. Use after treatment of retinal tears or retinal detachment. Arch Ophthalmol (1988) 0.90
Intravitreous fibronectin and platelet-derived growth factor. New model for traction retinal detachment. Arch Ophthalmol (1986) 0.90
Treatment of giant retinal tears combined with proliferative vitreoretinopathy. Ophthalmology (1986) 0.90
Extracellular matrix of newly forming vessels--an immunohistochemical study. Microvasc Res (1991) 0.89
Cataract extraction after vitrectomy. Ophthalmology (1987) 0.89
Intraocular pressure measurement after pars plana vitrectomy. Ophthalmology (1989) 0.88
Results of vitrectomy for proliferative diabetic retinopathy. Ophthalmology (1986) 0.88
Retinal microvessel extracellular matrix: an immunofluorescent study. Invest Ophthalmol Vis Sci (1986) 0.87
Clinicopathologic correlation of krypton red, argon blue-green, and argon green laser photocoagulation in the human fundus. Retina (1984) 0.87
Increased intraocular pressure after macular hole surgery. Am J Ophthalmol (1996) 0.85
Endothelial cells release a chemoattractant for retinal pigment epithelial cells in vitro. Arch Ophthalmol (1985) 0.85
Vitrectomy, fluid-gas exchange and transforming growth factor--beta-2 for the treatment of traumatic macular holes. Ophthalmology (1995) 0.85
Evolving concepts in the management of posterior segment penetrating ocular injuries. Retina (1990) 0.85
The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology (1986) 0.84
Effect of fibrin on morphologic characteristics of retinal pigment epithelial cells. Arch Ophthalmol (1984) 0.84
15-Hydroxyeicosatetraenoic acid stimulates migration of human retinal microvessel endothelium in vitro and neovascularization in vivo. Prostaglandins (1990) 0.83
Diabetic preretinal membranes. An immunohistochemical study. Arch Ophthalmol (1986) 0.83
Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2. Am J Ophthalmol (1994) 0.82
Fundus photographic and fluorescein angiographic characteristics of pseudoholes of the macula in eyes with epiretinal membranes. Ophthalmology (1995) 0.81
Retinal pigment epithelium cells can influence endothelial cell plasminogen activators. Invest Ophthalmol Vis Sci (1990) 0.81
Expression of recombinant diaminopimelate epimerase in Escherichia coli. Isolation and inhibition with an irreversible inhibitor. Eur J Biochem (1989) 0.81
Scleral indentation following cryotherapy and repeat cryotherapy enhance release of viable retinal pigment epithelial cells. Retina (1987) 0.81
A retina-derived stimulator(s) of retinal pigment epithelial cell and astrocyte proliferation. Exp Eye Res (1986) 0.80
Transforming growth factor-beta 2 levels increase following retinal laser photocoagulation. Curr Eye Res (1994) 0.80
Retinal pigment epithelial cells release a chemoattractant for astrocytes. Arch Ophthalmol (1985) 0.80
Low-dose colchicine inhibits astrocyte, fibroblast, and retinal pigment epithelial cell migration and proliferation. Arch Ophthalmol (1986) 0.80
Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol (1986) 0.80
Amiloride inhibition of angiogenesis in vitro. J Exp Zool (1993) 0.79
Degradation of basement membrane components by vascular endothelial cells: role in neovascularization. Ciba Found Symp (1983) 0.79
The effect of human intraocular fluid on vascular endothelial cell migration. Ophthalmology (1981) 0.79
Extraocular muscle imbalance after scleral buckling surgery. Ophthalmology (1989) 0.79
The use of perfluoro-octane in the management of giant retinal tears without proliferative vitreoretinopathy. Retina (1994) 0.78
Retinal hamartoma, acquired retinoschisis, and retinal hole. Am J Ophthalmol (1985) 0.78
Chemical mediators of intraocular neovascularization. Trans Ophthalmol Soc U K (1980) 0.78
Scleral outfolding for macular translocation. Am J Ophthalmol (2000) 0.77
Inhibition of retinal pigment epithelial cell attachment by a synthetic peptide derived from the cell-binding domain of fibronectin. Arch Ophthalmol (1986) 0.77
Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells. A new approach to the study of proliferative vitreoretinopathy. Arch Ophthalmol (1984) 0.77
High-performance liquid chromatographic method for quantitating plasma levels of amiloride and its analogues. J Chromatogr (1992) 0.77
Scleral buckle revision to treat recurrent rhegmatogenous retinal detachment. Ophthalmic Surg (1990) 0.77
Stimulation of endothelial cell prostacyclin release by retina-derived factors. Invest Ophthalmol Vis Sci (1988) 0.77
Mechanisms involved in retinal pigment epithelial cell chemotaxis. Arch Ophthalmol (1986) 0.76
Vitrectomy for nondiabetic vitreous hemorrhage. Retinal and choroidal vascular disorders. Retina (1988) 0.75
Role of lensectomy and posterior capsule in movement of tracers from vitreous to aqueous. Arch Ophthalmol (1985) 0.75
Vitrectomy for nondiabetic vitreous hemorrhage. Not associated with vascular disease. Retina (1988) 0.75
The surgical management of giant retinal tears with the cannulated extrusion needle. Am J Ophthalmol (1989) 0.75
Postoperative retinal breaks occurring after intravitreal silicone oil injection. Retina (1985) 0.75
Silicone oil for proliferative vitreoretinopathy. Does it help or hinder? Arch Ophthalmol (1988) 0.75
Cultured tumor cells produce chemotactic factors specific for endothelial cells: a possible mechanism for tumor-induced angiogenesis. Invasion Metastasis (1983) 0.75
Morphology of pig retinal pigment epithelium maintained in organ culture. Arch Ophthalmol (1988) 0.75
Surgical treatment of postoperative dilated, nonreactive pupil in eyes after combined pars plana lensectomy and vitrectomy. Retina (1990) 0.75
New and previously unidentified retinal breaks in eyes with recurrent retinal detachment with proliferative vitreoretinopathy. Arch Ophthalmol (1989) 0.75
Effect of lensectomy on the movement of tracers from vitreous to aqueous. Arch Ophthalmol (1984) 0.75
Inexpensive lightweight aspheric plastic indirect ophthalmoscopy lens. Am J Ophthalmol (1987) 0.75
Efficacy of fluid-air exchange during pars plana vitrectomy. Retina (1995) 0.75